Two of AstraZeneca’s most important drugs have received a boost, after European regulators backed a pen allowing people to inject themselves with respiratory drug Fasenra, and agreed that c
'Prevention' might be the buzzword of the moment in the pharma industry, but what does it actually mean for a company to intercept diseases before they even present clinically?
Caring for people with diabetic foot ulcers costs NHS England the region of £1 billion a year, but the developer of a new digital tool says it could help reduce the burden.
Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.
The American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and biotech firms unveiled latest data from therapies for
After moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on putting patients at the centre of the company and providing medical lead